Researchers at Memorial Sloan Kettering Cancer Center hope they can discover the safest dose for mesothelin‑targeted CAR T‑cell therapy.

This is the next step in ongoing research into whether this type of treatment helps fight malignant mesothelioma.

The cancer center is hosting the phase 1 trial, which is now recruiting. It has up to 30 spaces for patients with malignant pleural mesothelioma. The study is called a phase 1 “dose‑escalation trial,” which means the purpose is to determine dose amount combining safety and effectiveness.

 

What Is CAR T‑Cell Therapy?

CAR T‑cell therapy is a form of immunotherapy. Scientists and doctors manufacture cancer‑killing T‑cells in a laboratory. CAR is an acronym for chimeric antigen receptor.

CAR T‑cell therapy focuses on the mesothelin protein, which is overexpressed in cancers like mesothelioma. CAR is an engineered receptor that allows T‑cells to target specific proteins. If the CAR connects with mesothelin, then T‑cells are in striking distance to target the attached mesothelioma cell.

 

Specifics of the Study

The CAR T‑cell in this study is called “M28z1XXPD1DNR.” Memorial Sloan Kettering Cancer Center has conducted other CAR T‑cell therapy trials. One with the CAR T‑cell IcasM28z was used in a trial a few years ago for malignant mesothelioma.

This is, however, the first CAR T‑cell therapy trial involving an immune checkpoint inhibitor drug.

Doctors will also give an immune system‑suppressing drug to patients. The drug, cyclophosphamide, suppresses the PD‑1 protein on T‑cells. This protein usually links with the PD‑L1 protein on cancer cells. Blocking the protein keeps the immune system alert and on guard against mesothelioma.

According to the study’s page on clinicaltrials.gov, the CAR T‑cell therapy will be administered into the pleural cavity via a catheter or guided needle. Groups of three patients will be treated at up to 10 different dose levels.

If you’d like to join this exciting and unique trial, contact our team. Email our patient advocate, Karen Ritter, at karen@mesotheliomaguide.com. Even if this trial isn’t right for you, there may be another option to find emerging treatment for mesothelioma.

    Sources & Author

Devin Goldan image

About the Writer, Devin Golden

Devin Golden is the content writer for Mesothelioma Guide. He produces mesothelioma-related content on various mediums, including the Mesothelioma Guide website and social media channels. Devin's objective is to translate complex information regarding mesothelioma into informative, easily absorbable content to help patients and their loved ones.

Guide Packet Desktop Ad

Want to learn more?

Try Our Free Guide to Fighting Mesothelioma

Get in depth knowledge about your diagnosis & the best treatments.

Learn More
Guide Packet Mobile Ad

    Sources & Author

Picture of Devin Golden

About the Writer, Devin Golden

Devin Golden is the content writer for Mesothelioma Guide. He produces mesothelioma-related content on various mediums, including the Mesothelioma Guide website and social media channels. Devin's objective is to translate complex information regarding mesothelioma into informative, easily absorbable content to help patients and their loved ones.